argenx SE Investor Day Presentation Deck
Bullous Pemphigoid: Most Common Autoimmune Blistering
Disease
Severe, rare, chronic and recurrent autoimmune disorder characterized by fluid-filled blisters, itching and skin redness
PREVALENCE
argenx
BULLOUS PEMPHIGOID IS MEDIATED BY AUTOANTIBODIES
12 per 100,000¹
Increasing with aging population
Median age of onset
is 81 years
BURDEN
Severe blistering disease
Strong impact on quality of life
High mortality rate
2.40 (U.S.)²
No approved treatments
Topical/systemic corticosteroids,
steroid-sparing agents, rituximab,
IVlg
TREATMENT
Significant market opportunity with ~41K patients in the U.S.
(1) Wertenteil et al., J Am Acad Dermatol. 2019; (2) Tedbirt et al., JAMA Dermatol. 2021; argenx market research
UNMET NEED
Time to remission
High relapse rate
Side effects from corticosteroids
39View entire presentation